22.04.2014 • News • Mergers & Acquisitions (M&A) • AZ Electronic Materials • China Ministry of Commerce

Merck KGaA Again Extends Offer for AZ Electronic Materials

Germany's Merck KGaA has once again extended its offer for AZ Electronic Materials. The new completion date is May 2, pending antitrust clearance by China's ministry of commerce (MOFCOM).

Merck said discussions with MOFCOM are continuing and it is focusing its efforts on obtaining clearance as early as possible.

Since its last communication on the offer in mid-March, the Darmstadt-based chemicals and pharmaceuticals producer said it has been working to address unnamed "specific concerns" of the Chinese authorities.

"While Merck is confident that the concerns are addressable," CEO Karl-Ludwig Kley said "it is important for the stakeholders to know that we will follow the appropriate procedure in China."

As of Apr. 18, Merck had received valid acceptances of shareholders representing 67.53% of AZ's capital. Earlier, the company said it had lowered its acceptance threshold to 75% from 95%.

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Merck KGaA Again Extends Offer for AZ Electronic Materials